

Ref. No.: WOCK/SEC/SE/2022-23/030

12th August, 2022

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 Scrip Code: 532300	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 NSE Symbol: WOCKPHARMA
---	--

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('**Listing Regulations**'); and in continuation to our letter no. Ref. No.: WOCK/SEC/SE/2022-23/027 dated 4th August, 2022, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 12th August, 2022, inter-alia, have:

- i. approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2022; and Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company; and

Pursuant to Regulations 30 and 33 of Listing Regulations read with Schedule III of Listing Regulations, we also enclose herewith the following:

- a. Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2022; and Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company (enclosed as **Annexure I**).
- b. A copy of the Press Release proposed to be issued in respect of the said Financial Results (enclosed as **Annexure II**).

The meeting of the Board of Directors commenced at 02:15 p.m. and concluded at 3:45 p.m.

Kindly take the same on record please.

Thanking you,
for **Wockhardt Limited**



Debashis Dey
Company Secretary



B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited standalone financial results of Wockhardt Limited for the quarter ended 30 June, 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Wockhardt Limited ("the Company") for the quarter ended 30 June 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed,



Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

B S R & Co. LLP

or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248WW-100022

A handwritten signature in black ink, appearing to read 'Koosai Leheri', with a horizontal line underneath.

Koosai Leheri

Partner

Aurangabad

12 August 2022

Membership No.: 112399

UDIN:22112399AOVYPU5318

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

(Rs. In Crore except per share data)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2022


PARTICULARS	3 MONTHS ENDED 30/06/2022	3 MONTHS ENDED 31/03/2022	3 MONTHS ENDED 30/06/2021	YEAR ENDED 31/03/2022
	Unaudited	Audited (Refer Note 5)	Unaudited	Audited
(Refer notes below)				
1 Income				
(a) Revenue from operations	241	474	279	1,372
(b) Other income	49	22	15	38
Total income	290	496	294	1,410
2 Expenses				
(a) Cost of materials consumed	43	59	67	283
(b) Purchase of stock-in-trade	31	36	40	191
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	11	11	(0.31)	2
(d) Employee benefits expense	64	50	73	261
(e) Finance costs	61	78	55	273
(f) Depreciation and amortisation expense	47	43	42	171
(g) Other expenses	87	132	95	413
Total expenses	344	409	372	1,594
3 Profit/(Loss) before tax (1-2)	(54)	87	(78)	(184)
4 Tax expense:				
Current tax - credit	-	-	-	-
Tax pertaining to earlier years	-	5	-	5
Deferred tax - (credit)/charge - (Net)	(17)	42	(29)	(49)
5 Net Profit/ (Loss) after tax (3 ± 4)	(37)	40	(49)	(140)
6 Other Comprehensive Income				
i) Items that will not be reclassified to Profit or Loss - (charge)/credit (consisting of re-measurement of net defined benefit (liability)/asset)	(0.17)	(1)	(0.11)	(1)
ii) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge)	0.06	0.24	0.04	0.35
iii) Other Comprehensive Income (net of tax)	(0.11)	(1)	(0.07)	(1)
7 Total Comprehensive Income (5 ± 6(iii))	(37)	39	(49)	(141)
8 Paid-up equity share capital (face value of Rs. 5/- each)	72	72	55	72
9 Other Equity excluding Revaluation Reserves as per balance sheet				2,140
10 Earnings per share (face value of Rs. 5/- each) (*not annualised)				
(a) Basic (Rs.)	(2.62)*	3.24*	(4.05)*	(11.62)
(b) Diluted (Rs.)	(2.62)*	3.23*	(4.05)*	(11.62)

Notes To Standalone Results :-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 12, 2022. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) Revenue for the quarter and year ended March 31, 2022 includes Rs. 152 crore for assignment of intellectual property rights to one of its Subsidiary. The transaction has been eliminated in the Consolidated financial statements.
- 3) Basic and diluted earnings per share for prior periods have been adjusted appropriately for the bonus element in respect of issue of equity shares by way of rights issue that was completed during the quarter ended March 31, 2022.
- 4) The Company continues to monitor the impact of COVID-19 on its businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Company has exercised due care in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Company's financial results for the current period.
- 5) Figures for the quarter ended March 31, 2022 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of financial year 2021-22.
- 6) The Company is exclusively into Pharmaceutical business Segment.
- 7) All the amount have been rounded off to the nearest crore except per share data and as stated. Till December 31, 2021 all the amount have been rounded off to the nearest crore and two decimal thereof except per share data.
- 8) Previous period / year figures have been recast / re-grouped / re-classified wherever necessary, to conform to current period's classification.

Aurangabad
Date : August 12, 2022

FOR WOCKHARDT LIMITED



H F KHORAKIWALA

CHAIRMAN
DIN: 00045608



B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited consolidated financial results of Wockhardt Limited for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Wockhardt Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Wockhardt Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities.

Sr. No	Name of component	Relationship
1	Wockhardt Limited	Parent Company
2	Wockhardt UK Holdings Limited (including its following subsidiaries and its step-down subsidiaries) a) Wallis Group Limited b) The Wallis Laboratory Limited c) Wallis Licensing Limited d) Wockhardt Farmaceutica Do Brasil Ltda	Wholly Owned Subsidiary
3	Wockhardt Infrastructure Development Limited	Wholly Owned Subsidiary

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

4	Wockhardt Europe Limited (including its following wholly owned subsidiary) a) Wockhardt Nigeria Limited	Wholly Owned Subsidiary
5	Wockhardt Medicines Limited	Wholly Owned Subsidiary
6	Wockhardt Biologics Limited	Wholly Owned Subsidiary
7	Wockhardt Bio AG (including its following subsidiaries and its step-down subsidiaries) a) CP Pharmaceuticals Limited b) CP Pharma (Schweiz) AG c) Z & Z Services GmbH d) Wockhardt UK Limited e) Wockpharma Ireland Limited f) Pinewood Laboratories Limited g) Pinewood Healthcare Limited h) Laboratories Negma S.A.S. i) Wockhardt France (Holdings) S.A.S. j) Wockhardt Holding Corp. k) Wockhardt USA LLC l) Morton Grove Pharmaceuticals Inc. m) MGP Inc. n) Laboratories Pharma 2000 S.A.S. o) Niverpharma S.A.S. p) Negma Beneulex S.A. q) Phytex S.A.S. r) Wockhardt Farmaceutica SA DE CV s) Wockhardt Services SA DE CV t) Wockhardt Bio (R) LLC u) Wockhardt Bio Pty Limited v) Wockhardt Bio Limited	Subsidiary

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial information of five subsidiaries included in the Statement, whose financial information reflects total revenue (before consolidation adjustments) of Rs. 574 crores, total net profit after tax (before consolidation adjustment) of Rs. 27 crores and total comprehensive income (before consolidation adjustment) of Rs. 23 crores, for the quarter ended 30 June 2022, as considered in the unaudited consolidated financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the financial information of 21 Subsidiaries which have not been reviewed, whose financial information reflect total revenue (before consolidation adjustments) of Rs. 19 crores, total net profit after tax (before consolidation adjustments) of Rs. 7 crores and total comprehensive income of Rs. 7 crores for the quarter ended 30 June 2022, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Koosai Lehery

Partner

Aurangabad

12 August 2022

Membership No.: 112399

UDIN:22112399AOVYKR7085

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Aurangabad - 431 006
 Global Headquarters: Wockhardt Towers, Bandra Kuria Complex, Bandra (East), Mumbai 400 051
 CIN: L24230MH1999PLC120720
 Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. In Crore except per share data)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

	PARTICULARS (Refer Notes Below)	3 MONTHS ENDED 30/06/2022	3 MONTHS ENDED 31/03/2022	3 MONTHS ENDED 30/06/2021	YEAR ENDED 31/03/2022
		Unaudited	Audited (Refer Note 7)	Unaudited	Audited
1	Income				
	(a) Revenue from operations	595	655	860	3,230
	(b) Other income	57	14	14	20
	Total income	652	669	874	3,250
2	Expenses				
	(a) Cost of materials consumed	140	161	150	612
	(b) Purchase of stock-in-trade	115	116	143	568
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(28)	(2)	31	87
	(d) Employee benefits expense	180	181	192	749
	(e) Finance costs	73	86	64	299
	(f) Depreciation and amortisation expense	64	59	64	247
	(g) Other expenses	204	232	236	916
	Total expenses	748	833	880	3,478
3	Loss before exceptional items and tax (1-2)	(96)	(164)	(6)	(228)
4	Exceptional items- charge (Refer note 3)	-	(183)	-	(183)
5	Loss after exceptional items and before tax (3 ± 4)	(96)	(347)	(6)	(411)
6	Tax expense:				
	Current tax - (credit)/ charge	4	(4)	9	33
	Tax pertaining to earlier years	-	5	-	5
	Deferred tax - credit (Net)	(25)	(37)	(8)	(170)
7	Net Loss after tax (5 ± 6)	(75)	(311)	(7)	(279)
	Attributable to :				
	Equity shareholders of the Company	(67)	(258)	(13)	(244)
	Non - Controlling Interest	(8)	(53)	6	(35)
8	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset)	(6)	(7)	(6)	(24)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge)	1	1	1	5
	(c) Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations)	(15)	1	51	(8)
	(d) Other Comprehensive Income (net of tax) (a ± b ± c)	(20)	(5)	46	(27)
9	Total Comprehensive Income (7 ± 8 (d))	(95)	(316)	39	(306)
	Attributable to :				
	Equity shareholders of the Company	(94)	(270)	24	(276)
	Non - Controlling Interest	(1)	(46)	15	(30)
10	Paid-up equity share capital (face value of Rs. 5/- each)	72	72	55	72
11	Other Equity excluding Revaluation Reserves as per Balance Sheet				3,777
12	Earnings per equity share (face value of Rs. 5/- each) (*not annualised)				
	(a) Basic (Rs.)	(4.64)*	(21.20)*	(1.05)*	(20.24)
	(b) Diluted (Rs.)	(4.64)*	(21.20)*	(1.05)*	(20.24)

TD

TW

Notes To Consolidated Results:

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 12, 2022. The results have been subjected to limited review by the Statutory Auditors of the Company.
- 2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- 3) Wockhardt USA LLC, Morton Grove Pharmaceuticals, Inc., and Wockhardt Limited (collectively "Wockhardt") have entered into a settlement term sheet agreement with the State of Texas on February 8, 2022 in regard to Civil Investigative Demand ('CID') with respect to submission of price information and updates to Texas Medicaid. Wockhardt has agreed to pay USD 36 million and interest over nine instalments between 2022 and 2025.
During the previous year and quarter ended March 31, 2022 the Company has created additional provision and presented Rs. 183 crores (charge for the year) based on its present value as an 'Exceptional Items'.
- 4) Basic and diluted earnings per share for prior periods have been adjusted appropriately for the bonus element in respect of issue of equity shares by way of rights issue that was completed during the quarter ended March 31, 2022.

5) Key Financials on Standalone basis:

(Rs. in Crore)


PARTICULARS	3 MONTHS ENDED 30/06/2022	3 MONTHS ENDED 31/03/2022	3 MONTHS ENDED 30/06/2021	YEAR ENDED 31/03/2022
	Unaudited	Audited	Unaudited	Audited
Total Income	290	496	294	1,410
Profit/ (Loss) before tax	(54)	87	(78)	(184)
Profit/ (Loss) after tax	(37)	40	(49)	(140)

Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

- 6) The Group continues to monitor the impact of COVID-19 on its businesses across the globe, its customers, vendors, employees, productions, supply chain and logistics etc. The Group has exercised due care in significant accounting judgements and estimates in relation to recoverability of receivables, investments and inventories based on the information available to date, both internal and external, while preparing the Group's financial results for the current period.
- 7) Figures for the quarter ended March 31, 2022 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of financial year 2021-22.
- 8) The Group is exclusively into Pharmaceutical business Segment.
- 9) For List of Subsidiaries as on June 30, 2022 please refer Annexure.
- 10) All the amount have been rounded off to the nearest crore except per share data. Till December 31, 2021 all the amount have been rounded off to the nearest crore and two decimal thereof except per share data.
- 11) Previous period / year figures have been recast / re-grouped / re-classified wherever necessary, to conform to current period's classification

Aurangabad
Date : August 12, 2022

FOR WOCKHARDT LIMITED



H F KHORAKIWALA
CHAIRMAN
DIN: 00045608



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalhana, Aurangabad - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

Annexure to Note 9 of Consolidated unaudited results for the quarter ended June 30, 2022

List of Subsidiaries as on June 30, 2022

- 1 Wockhardt UK Holdings Limited
- 2 CP Pharmaceuticals Limited
- 3 CP Pharma (Schweiz) AG
- 4 Wallis Group Limited
- 5 The Wallis Laboratory Limited
- 6 Wockhardt Farmaceutica Do Brasil Ltda
- 7 Wallis Licensing Limited
- 8 Wockhardt Infrastructure Development Limited
- 9 Z & Z Services GmbH
- 10 Wockhardt Europe Limited
- 11 Wockhardt Nigeria Limited
- 12 Wockhardt USA LLC
- 13 Wockhardt UK Limited
- 14 Wockpharma Ireland Limited
- 15 Pinewood Laboratories Limited
- 16 Pinewood Healthcare Limited
- 17 Laboratoires Negma S.A.S.
- 18 Wockhardt France (Holdings) S.A.S.
- 19 Wockhardt Holding Corp.
- 20 Morton Grove Pharmaceuticals Inc.
- 21 MGP Inc.
- 22 Laboratoires Pharma 2000 S.A.S.
- 23 Niverpharma S.A.S.
- 24 Negma Beneulex S.A.
- 25 Phytex S.A.S.
- 26 Wockhardt Farmaceutica SA DE CV
- 27 Wockhardt Services SA DE CV
- 28 Wockhardt Bio AG
- 29 Wockhardt Bio (R) LLC
- 30 Wockhardt Bio Pty Limited
- 31 Wockhardt Bio Limited
- 32 Wockhardt Medicines Limited
- 33 Wockhardt Biologics Limited

Wockhardt Limited

Registered Office:
D-4, MIDC, Chikalthana
Aurangabad - 431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720
www.wockhardt.com



Mumbai, 12th August, 2022

**Wockhardt's Q1 FY23 EBITDA at Rs.(16 cr)
EBITDA before R&D at Rs.20 cr**

Particulars	Q1 FY23	Q4 FY22	Q1 FY22
	INR Cr	INR Cr	INR Cr
Sales	595	655	860
EBITDA before R&D	20	(7)	142
EBITDA % to Sales	3.3%	-1.0%	16.5%
R&D	36	26	34
R&D % to Sales	6.0%	4.0%	4.0%
EBITDA	(16)	(33)	108
EBITDA Margins %	-2.7%	-5.0%	12.6%
Exceptional Items #	-	(183)	-
PBT	(96)	(347)	(6)
Profit After Tax	(67)	(258)	(13)
PAT Margins %	-11.3%	-39.4%	-1.5%

Exceptional items represent,

- For Q4 FY22, the final provision made by the US subsidiaries of the Company towards Net Present Value of the amount payable to the State of Texas as per the settlement entered into between the US subsidiaries and the State of Texas in regard to Civil Investigative Demand with respect to submission of price information and updates to Medicaid.

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 1st Quarter Results for Financial Year 2022-23, today.



The Company recorded a Revenue of Rs.595 Cr in Q1FY23 compared to Rs. 655 Cr in previous quarter registering a de-growth of 9%. EBITDA for the quarter is Rs.(16) Cr as compared to Rs.(33) Cr in Q4FY22.

The corresponding quarter of previous year includes revenue & profitability from UK Vaccines business.

Business Review:

Quarter ended 30th June, 2022:

- **UK Business** stood at Rs.196 Cr in Q1FY23 (PY Rs.407 Cr). UK Business contributed about 33% of Global Revenue.
- **India Business:** India Business stood at Rs.158 Cr showing a growth of 4% compared to PY. India Business contributed 27% of the Global Revenue. EMROK, the NCE launched during FY21 continues to provide unmatched benefits to the patients.
- **Emerging Markets Business** of the Company stood at Rs.117 Cr in Q1FY23 (PY Rs.124 Cr). Emerging Markets Business contributed about 20% of the Global Revenue.
- **Irish Business** stood at Rs.37 Cr in Q1FY23 (PY Rs.36 Cr).
- **US Business** stood at Rs.74 Cr in Q1FY23 (PY Rs.102 Cr). US Business contributed 12% of the Global Revenue. US business was impacted by price erosion and supply disruptions.

Research and Development expenditure during the quarter was at Rs.36 Cr (6% to sales) and including capital expenditure was at 10.7% to sales.

Intellectual Property (IP):

7 patents were filed during the quarter ended 30th June, 2022 and the cumulative filings till date are 3235. The company was granted 1 patent during the quarter and now holds 804 patents.



Wockhardt Limited
Registered Office:
D-4, MIDC, Chikalthana
Aurangabad - 431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720
www.wockhardt.com

About Wockhardt:

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing over ~4000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 73% of its global revenues coming from international businesses.